BKD vs. SAGE, WRBY, MDXG, CRGX, ETNB, BCRX, DAWN, EYPT, DCPH, and COLL
Should you be buying Brookdale Senior Living stock or one of its competitors? The main competitors of Brookdale Senior Living include Sage Therapeutics (SAGE), Warby Parker (WRBY), MiMedx Group (MDXG), CARGO Therapeutics (CRGX), 89bio (ETNB), BioCryst Pharmaceuticals (BCRX), Day One Biopharmaceuticals (DAWN), EyePoint Pharmaceuticals (EYPT), Deciphera Pharmaceuticals (DCPH), and Collegium Pharmaceutical (COLL). These companies are all part of the "medical" sector.
Sage Therapeutics (NASDAQ:SAGE) and Brookdale Senior Living (NYSE:BKD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings.
In the previous week, Sage Therapeutics had 6 more articles in the media than Brookdale Senior Living. MarketBeat recorded 9 mentions for Sage Therapeutics and 3 mentions for Brookdale Senior Living. Brookdale Senior Living's average media sentiment score of 0.84 beat Sage Therapeutics' score of 0.34 indicating that Sage Therapeutics is being referred to more favorably in the media.
Brookdale Senior Living has higher revenue and earnings than Sage Therapeutics. Brookdale Senior Living is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.
Brookdale Senior Living has a net margin of -6.27% compared to Brookdale Senior Living's net margin of -626.32%. Sage Therapeutics' return on equity of -44.01% beat Brookdale Senior Living's return on equity.
Sage Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Brookdale Senior Living has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.
99.2% of Sage Therapeutics shares are held by institutional investors. 5.5% of Sage Therapeutics shares are held by insiders. Comparatively, 1.5% of Brookdale Senior Living shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Sage Therapeutics presently has a consensus target price of $41.00, suggesting a potential upside of 117.62%. Brookdale Senior Living has a consensus target price of $7.50, suggesting a potential upside of 12.44%. Given Brookdale Senior Living's higher probable upside, equities analysts plainly believe Sage Therapeutics is more favorable than Brookdale Senior Living.
Sage Therapeutics received 161 more outperform votes than Brookdale Senior Living when rated by MarketBeat users. Likewise, 68.76% of users gave Sage Therapeutics an outperform vote while only 66.96% of users gave Brookdale Senior Living an outperform vote.
Summary
Sage Therapeutics beats Brookdale Senior Living on 10 of the 18 factors compared between the two stocks.
Get Brookdale Senior Living News Delivered to You Automatically
Sign up to receive the latest news and ratings for BKD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Brookdale Senior Living Competitors List
Related Companies and Tools